A global pharmaceutical company based in France has licensed software developed by San Diego digital health startup CureMatch that aims to help cancer doctors customize the combination of drugs they prescribe to patients based on mutations in cancer DNA.
CureMatch was founded in 2015 to commercialize technology developed at the UC San Diego Moores Cancer Center. The company, which CEO Bob Manning says has raised about $2.5 million in outside investment, says its software can help guide customized care by using a patient’s genetic information to score and rank treatment options. It calls the guides it produces PreciGENE reports.
Now it… Read more »
UNDERWRITERS AND PARTNERS
